Classifying squamous cell carcinoma of the head and neck: prognosis, prediction and implications for therapy

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11–30 (2013).
   PubMed Web of Science ®Google Scholar
• Young JL, Ward KC, Ries LAG. Cancers of rare sites. In: SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988–2001, Patient and Tumor Characteristics. Ries Lag YJ, Keel Ge, Eisner Mp, Lin Yd, Horner M-J (Eds). National Cancer Institute, SEER Program, NIH Pub. No. 07–6215 Bethesda, MD, USA (2007).
   Google Scholar
• Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363(1), 24–35 (2010).
   PubMed Web of Science ®Google Scholar
• O’Sullivan B, Huang SH, Siu LL et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J. Clin. Oncol. 31(5), 543–550 (2013).
   PubMed Web of Science ®Google Scholar
• Maxwell JH, Kumar B, Feng FY et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin. Cancer Res. 16(4), 1226–1235 (2010).
   PubMedGoogle Scholar
• Nakao Y, Yang X, Yokoyama M et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br. J. Cancer 75(10), 1410–1416 (1997).
   PubMedGoogle Scholar
• Weinberger PM, Yu Z, Haffty BG et al. Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J. Clin. Oncol. 24(5), 736–747 (2006).
   PubMed Web of Science ®Google Scholar
• Rischin D, Young RJ, Fisher R et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J. Clin. Oncol. 28(27), 4142–4148 (2010).
   PubMed Web of Science ®Google Scholar
• Michaud WA, Nichols AC, MrozEA et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 15(5), 1645–1654 (2009).
   PubMedGoogle Scholar
• Nichols AC, Finkelstein DM, Faquin WC et al. Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin. Cancer Res. 16(7), 2138–2146 (2010).
   PubMedGoogle Scholar
• Rubin Grandis J, Melhem MF, Gooding WE et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst. 90(11), 824–832 (1998).
   PubMed Web of Science ®Google Scholar
• Chung CH, Ely K, McGavran L et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 24(25), 4170–4176 (2006).
   PubMed Web of Science ®Google Scholar
• Temam S, Kawaguchi H, El-Naggar AK et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J. Clin. Oncol. 25(16), 2164–2170 (2007).
   PubMed Web of Science ®Google Scholar
• Hama T, Yuza Y, Saito Y et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14(9), 900–908 (2009).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116–1127 (2008).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 23(34), 8646–8654 (2005).
   PubMed Web of Science ®Google Scholar
• Kumar B, Cordell KG, Lee JS et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J. Clin. Oncol. 26(19), 3128–3137 (2008).
   PubMed Web of Science ®Google Scholar
• Reimers N, Kasper HU, Weissenborn SJ et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int. J. Cancer 120(8), 1731–1738 (2007).
   PubMed Web of Science ®Google Scholar
• Stoehlmacher-Williams JVC, Foa P, Rottey S et al. Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial. J. Clin. Oncol. 30(Suppl.), Abstract 5504 (2012).
   Google Scholar
• Giralt J FA, Mesia R, Minn H et al. A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J. Clin. Oncol. 30(Suppl.) Abstract 5502 (2012).
   PubMedGoogle Scholar
• Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol. Cancer 4(1), 18 (2005).
   PubMedGoogle Scholar
• Zhang R, Niu Y, Zhou Y. Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol Lett. 192(2), 108–114 (2010).
   PubMedGoogle Scholar
• Park SY, Lam W, Cheng YC. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res. 62(2), 459–465 (2002).
   PubMedGoogle Scholar
• Ang MK, Patel MR, Yin XY et al. High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 17(20), 6542–6552 (2011).
   PubMedGoogle Scholar
• Jun HJ, Ahn MJ, Kim HS et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br. J. Cancer 99(1), 167–172 (2008).
   PubMedGoogle Scholar
• Handra-Luca A, Hernandez J, Mountzios G et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin. Cancer Res. 13(13), 3855–3859 (2007).
   PubMedGoogle Scholar
• Nix P, Greenman J, Stafford N, Cawkwell L. Expression of XRCC 1 and ERCC 1 proteins in radioresistant and radiosensitive laryngeal cancer. Cancer Therapy 2, 47–53 (2004).
   Google Scholar
• Hanken H, Grobe A, Cachovan G et al. CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clin. Oral Investig. 15, 15 (2013).
   Google Scholar
• Pignataro L, Pruneri G, Carboni N et al. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. J. Clin. Oncol. 16(9), 3069–3077 (1998).
   PubMedGoogle Scholar
• Dong Y, Sui L, Sugimoto K, Tai Y, Tokuda M. Cyclin D1-CDK4 complex, a possible critical factor for cell proliferation and prognosis in laryngeal squamous cell carcinomas. Int. J. Cancer 95(4), 209–215 (2001).
   PubMedGoogle Scholar
• Bova RJ, Quinn DI, Nankervis JS et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin. Cancer Res. 5(10), 2810–2819 (1999).
   PubMedGoogle Scholar
• Yu Z, Weinberger PM, Haffty BG et al. Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 11(3), 1160–1166 (2005).
   PubMedGoogle Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Van De Vijver MJ, He YD, Van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Yin X, Hoadley KA et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin. Cancer Res. 16(19), 4864–4875 (2010).
   PubMed Web of Science ®Google Scholar
• Walter V, Yin X, Wilkerson MD et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS ONE 8(2), e56823 (2013).
   PubMed Web of Science ®Google Scholar
• Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur. J. Cancer 43(2), 415–432 (2007).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Brodowicz T, Shepherd FA et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J. Thorac. Oncol. 6(1), 64–70 (2011).
   PubMed Web of Science ®Google Scholar
• Kandoth C, Schultz N, Cherniack AD et al. Integrated genomic characterization of endometrial carcinoma. Nature 497(7447), 67–73 (2013).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368(22), 2059–2074 (2013).
   PubMed Web of Science ®Google Scholar